M., A., M., A., A., M. (2019). COMPARATIVE STUDY BETWEEN INTRAVITREAL VERSUS SUBTENON INJECTION OF TRIAMCINOLONE ACETONIDE IN MANAGEMENT OF DIABETIC MACULAR OEDEMA. Egyptian Journal of Clinical Ophthalmology, 2(2), 57-68. doi: 10.21608/ejco.2019.162985
Abd El-Rahman, M.; Abd El-badie, M.; Mohamed, A.. "COMPARATIVE STUDY BETWEEN INTRAVITREAL VERSUS SUBTENON INJECTION OF TRIAMCINOLONE ACETONIDE IN MANAGEMENT OF DIABETIC MACULAR OEDEMA". Egyptian Journal of Clinical Ophthalmology, 2, 2, 2019, 57-68. doi: 10.21608/ejco.2019.162985
M., A., M., A., A., M. (2019). 'COMPARATIVE STUDY BETWEEN INTRAVITREAL VERSUS SUBTENON INJECTION OF TRIAMCINOLONE ACETONIDE IN MANAGEMENT OF DIABETIC MACULAR OEDEMA', Egyptian Journal of Clinical Ophthalmology, 2(2), pp. 57-68. doi: 10.21608/ejco.2019.162985
M., A., M., A., A., M. COMPARATIVE STUDY BETWEEN INTRAVITREAL VERSUS SUBTENON INJECTION OF TRIAMCINOLONE ACETONIDE IN MANAGEMENT OF DIABETIC MACULAR OEDEMA. Egyptian Journal of Clinical Ophthalmology, 2019; 2(2): 57-68. doi: 10.21608/ejco.2019.162985
COMPARATIVE STUDY BETWEEN INTRAVITREAL VERSUS SUBTENON INJECTION OF TRIAMCINOLONE ACETONIDE IN MANAGEMENT OF DIABETIC MACULAR OEDEMA
Ophthalmology dept., Faculty of Medicine, Al-Azhar Univ., Assiut, Egypt
Abstract
Purpose: To study the difference in the both safety and efficacy of Intravitreal (IVTA)versus subtenon (STTA ) triamcinolone acetonide injection as a treatment approach of diabetic macular edema (DME). Patients and Methods: 50 eyes of 38 diabetic patients diagnosed DME according to the ETDRS criteria were divided into two groups; each group consists of twenty five eyes. Group A were injected IVTA with 4 mg (0.1ml). Group B were injected STTA with 40 mg (1ml). Results: In group Awe found that the mean central macular thickness (CMT) reduced from 465.6 u ± 170.8 u at the baseline level to 285.9 u ± 83.2 u,267.5 u ± 79 u and 288.4u ±169.8uat 1,3 and 6 months post injection respectively. In group B we found that the mean CMT reduced from 327.65u ± 68.4 u at the baseline level to 273.2 u ± 77.9, 257.8u ± 83.6u and 264.9u ±104.3uat 1.3 and 6 months post injection respectively. In group A we found that the mean visual acuity (VA) was improved from 0.2 at the baseline to 0.4, 0.3 and 0.4 at 1, 3 and 6 months post injection respectively. In group B we found that the mean VA was improved from 0.3 at the baseline to 0.5, 0.7 and 0.7at 1.3 and 6 months post injection respectively. In group A we found that the mean intra ocular pressure (IOP)was changed from 16.2 mmHg ±1.2 mmHg at the baseline to20.9 mmHg ±6.9 mmHg, 17.4 mmHg ±1.6 mm Hg and 17.4 mmHg ±1.6 mmHg at 1,3 and 6 months post injection respectively. In group B we found that the mean IOP was changed from15.15mmHg ±1.8 mmHg at the baseline to15.6 mmHg ±1.8 mmHg, 15.8mmHg ±1.8 mmHg and15.7 mmHg ±1.8mmHg at 1.3 and 6 months post injection respectively. Conclusion: STTA can achieve clinical results comparable to IVTA as regards the reduction of CMT and the improvement of VA although it achieves this effect somewhat slower.